Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Autor: Leila N. Atmowihardjo, Job R. Schippers, Erik Duijvelaar, Imke H. Bartelink, Pierre M. Bet, Noortje E. L. Swart, Nienke van Rein, Keith Purdy, David Cavalla, Andrew McElroy, Sarah Fritchley, Anton Vonk Noordegraaf, Henrik Endeman, Patricia van Velzen, Matty Koopmans, Harm Jan Bogaard, Leo Heunks, Nicole Juffermans, Marcus J. Schultz, Pieter R. Tuinman, Lieuwe D. J. Bos, Jurjan Aman

Publikováno v: Critical Care, Vol 27, Iss 1, Pp 1-13 (2023)

Abstract Purpose A hallmark of acute respiratory distress syndrome (ARDS) is hypoxaemic respiratory failure due to pulmonary vascular hyperpermeability. The tyrosine kinase inhibitor imatinib reversed pulmonary capillary leak in preclinical studies a

Externí odkaz: https://doaj.org/article/9b66fd0c759d40f6b53c6782c1837294

Glucocorticoid Receptor (GR) antagonism as disease-modifying treatment for MDD with childhood trauma: protocol of the RESET-medication randomized controlled trial

Autor: F. Linsen, C. Broeder, M. S. C. Sep, J. E. Verhoeven, P. M. Bet, B. W. J. H. Penninx, O. C. Meijer, C. H. Vinkers

Publikováno v: BMC Psychiatry, Vol 23, Iss 1, Pp 1-11 (2023)

Abstract Background Major depressive disorder (MDD) is a heterogeneous psychiatric disorder. Childhood trauma (CT, emotional/physical/sexual abuse or neglect before the age of 18) is one of the largest and most consistent risk factors for development

Externí odkaz: https://doaj.org/article/392365ce87254f0ba560ee373f329931

Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study

Autor: Imke H. Bartelink, Pierre M. Bet, Nicolas Widmer, Monia Guidi, Erik Duijvelaar, Bram Grob, Richard Honeywell, Amanda Evelo, Ivo P. E. Tielbeek, Sue D. Snape, Henrike Hamer, Laurent A. Decosterd, Harm Jan Bogaard, Jurjan Aman, Eleonora L. Swart

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1497-1511 (2021)

Abstract This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID‐19). Total (bound + unbound) and unbound imatinib pl

Externí odkaz: https://doaj.org/article/84259887a4a245ea94b698c03f036179

Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice

Autor: R. van Westrhenen, R. H. N. van Schaik, T. van Gelder, T. K. Birkenhager, P. R. Bakker, E. J. F. Houwink, P. M. Bet, W. J. G. Hoogendijk, M. J. M. van Weelden-Hulshof

Publikováno v: Frontiers in Pharmacology, Vol 12 (2021)

Effective pharmacologic treatments for psychiatric disorders are available, but their effect is limited due to patients’ genetic heterogeneity and low compliance-related to frequent adverse events. Only one third of patients respond to treatment an

Externí odkaz: https://doaj.org/article/7598e28a637d4ebd86252e89be015fee

A new approach to drug intravenous compatibility research: The case of obstetric parenteral drugs

Autor: A F Leeuwerik, L N van Merendonk, M A de Boer, A J Wilhelm, A Kolkman, P M Bet

Publikováno v: European Journal of Hospital Pharmacy. European Association of Hospital Pharmacists (EAHP)
Leeuwerik, A F, van Merendonk, L N, de Boer, M A, Wilhelm, A J, Kolkman, A & Bet, P M 2023, ' A new approach to drug intravenous compatibility research : The case of obstetric parenteral drugs ', European Journal of Hospital Pharmacy . https://doi.org/10.1136/ejhpharm-2022-003577

Objectives: The product information and literature does not provide confirmation of compatibility for co-administration of all commonly used drug pairs in obstetrics. However, there is a need for co-administration of these drugs over one lumen for th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5600783a585c7f3022de59bfdb4f2133
https://research.vumc.nl/en/publications/26e92c26-3659-4100-8491-95ab3ee8e8a5